natgillin/translations-raw huggingface dataset:
Sitagliptin on its own as Januvia/Xelevia/Tesavel can be used with metformin, and with both metformin and a sulphonylurea, in type 2 diabetes patients.
Samostalno, pod nazivima Januvia/Xelevia/Tesavel, sitagliptin se može koristiti kao metformin, te s metforminom i sulfonilurejom u bolesnika s dijabetesom tipa 2.
Sitagliptin phosphate is an orally-active, potent, and highly selective inhibitor of the dipeptidyl peptidase 4 (DPP-4) enzyme for the treatment of type 2 diabetes.
Sitagliptinfosfat je potentan i vrlo selektivan oralni inhibitor enzima dipeptidil peptidaze 4 (DPP-4), namijenjen liječenju dijabetesa tipa 2.
Sitagliptin was modestly removed by haemodialysis (13.5 % over a 3- to 4-hour haemodialysis session starting hours post-dose).
Sitagliptin se umjereno uklanja hemodijalizom (13,5% nakon dijalize u trajanju 3-4 sata započete 4 sata nakon doze lijeka).
Sitagliptin2
glargin inzulin1
site conditions
malaksalost
SITE CONDITIONS
MJESTU PRIMJENE
site conditions
na mjestu primjene
site conditions
Opći poremećaji i reakcije na mjestu primjene
site conditions
reakcije na
site haematoma Puncture site haemorrhage
hematom na mjestu uboda u krvnu žilu, krvarenje na mjestu uboda
Site-directed mutagenesis of known NS5A RAVs showed that substitutions conferring a > 100-fold reduction in velpatasvir susceptibility are M28G, A92K and Y93H/N/R/W in genotype 1a, A92K in genotype 1b, C92T and Y93H/N in genotype 2b, Y93H in genotype 3, and L31V and P32A/L/Q/R in genotype 6.
Ciljane mutageneze poznatih RAV-ova NS5A pokazale su da su supstitucije koje su dovele do smanjene osjetljivosti velpatasvitra za > 100 puta bile M28G, A92K i Y93H/N/R/W u genotipu 1a, A92K u genotipu 1b, C92T i Y93H/N u genotipu 2b, Y93H u genotipu 3 te L31V iP32A/L/Q/R u genotipu 6.
Sites of administration should alternate between the left and the right anterolateral and left and right posterolateral abdominal wall.
naizmjenično aplicirati u lijevu i desnu anterolateralnu, te lijevu i desnu posterolateralnu trbušnu stijenku.
Sites responsible for Batch Release in the EEA:-
Lokacije odgovorne za puštanje serije lijeka u promet u EEA:
Situations in which you must not start or continue to use insulin pumps are described in the operating manuals for these pumps.
Okolnosti u kojima ne smijete početi niti nastaviti s uporabom inzulinskih pumpi opisane su u priručniku za njihovu uporabu.
Sivextro 200 mg powder for concentrate tedizolid phosphate
Sivextro 200 mg prašak za koncentrat tedizolidfosfat
Sivextro is a white to off-white powder for concentrate for solution for infusion in a glass vial.
Sivextro je bijeli do bjelkasti prašak za koncentrat za otopinu za infuziju u staklenoj bočici.
Sivextro is an oval, yellow film-coated tablet imprinted with ‘TZD’ on one side and ‘200’ on the other side.
Sivextro je ovalna, žuta filmom obložena tableta s utisnutom oznakom "TZD" na jednoj strani i "200" na drugoj strani.
Sivextro’s safety profile is comparable to that of linezolid and was considered acceptable.
Sigurnosni profil lijeka Sivextro usporediv je s profilom linezolida i smatran je prihvatljivim.
Six Bortezomib Hospira cycles are recommended, although for patients with a response first documented at cycle 6, two additional Bortezomib Hospira cycles may be given.
Preporučuje se šest ciklusa liječenja lijeka Bortezomib Hospira, iako se bolesnicima za koje je odgovor prvi put zabilježen u 6. ciklusu, mogu dati dva dodatna ciklusa liječenja lijekom Bortezomib Hospira.
Six Bortezomib SUN cycles are recommended, although for patients with a response first documented at cycle 6, two additional Bortezomib SUN cycles may be given.
Preporučuje se šest ciklusa liječenja Bortezomib SUN-om, iako se bolesnicima za koje je odgovor prvi put zabilježen u 6. ciklusu mogu dati dva dodatna ciklusa liječenja Bortezomib SUN- om.
Six cases of Stevens-Johnson Syndrome were reported in the study; all but one occurred within the first 30 days of nevirapine treatment.
Prijavljeno je šest slučajeva Stevens-Johnsonovog sindroma u ispitivanju, a osim jednog su se pojavili unutar prvih 30 dana liječenja nevirapinom.
Six months after the first dose, the seroprotection rate was as follows:
Šest mjeseci nakon prve doze zabilježene su sljedeće vrijednosti stopa seroprotekcije:
Six months seizure freedom
Šest mjeseci bez napadaja
Six of 143 (4%) adult patients with CLD receiving eltrombopag experienced TEEs (all of the portal venous system) and two of 145 (1%) subjects in the placebo group experienced TEEs (one in the portal venous system and one myocardial infarction).
TED je doživjelo šest od 143 (4%) odraslih bolesnika s kroničnom bolešću jetre koji su primali eltrombopag (svi u sustavu vene porte), te dvoje od 145 (1%) ispitanika u grupi s placebom (jedan u sustavu vene porte i jedan infarkt miokarda).
Six of these 11 (55 %) patients had mean indinavir plasma concentrations 8 hours post- dose (Cmin) below assay threshold of reliable quantification.
U 6 od navedenih 11 (55%) bolesnica srednje koncentracije indinavira u plazmi 8 sati nakon primjene doze (Cmin) bile su ispod granice pouzdane mjerljivosti.
Six open-label studies evaluated Oncaspar in relapse/refractory haematological diseases.
Šest otvorenih ispitivanja procjenjivalo je Oncaspar u relapsnim/refraktornim hematološkim bolestima.
Six patients (1 in the 12-week, 5 in the 24-week treatment group) with HCV RNA < LLOQ at last measurement prior to transplant, were transplanted prior to SVR12 and were excluded from SVR12 and relapse analyses.
Nazivnik za relaps je broj pacijenata s HCV RNK < LLOQ na njihovom posljednjem pregledu za vrijeme trajanja terapije.
Six patients with initial levels below 200µg/g achieved, at week 24, a level of ≥200 µg/g.
Šest bolesnika s početnim razinama ispod 200 μg/g postiglo je u 24. tjednu razinu od ≥ 200 μg/g.
Six treatment cycles, each of 28 day duration, followed by maintenance once every two months for two years or until disease progression (whichever occurs first).
Šest ciklusa liječenja, od kojih svaki traje 28 dana, nakon kojih slijedi terapija održavanja jedanput svaka dva mjeseca tijekom dvije godine ili do progresije bolesti (što god nastupi prije).
Six treatment cycles, each of 28 day duration, followed by maintenance once every two months for two years or until disease progression (whichever occurs first).
Šest ciklusa liječenja, od kojih svaki traje 28 dana, nakon kojih slijedi terapija održavanja jedanput svaka dva mjeseca tijekom dvije godine ili do progresije bolesti (što god nastupi ranije).
Six treatment cycles, each of 28 day duration.
Šest ciklusa liječenja, od kojih svaki traje 28 dana.
Six VELCADE cycles are recommended, although for patients with a response first documented at cycle 6, two additional VELCADE cycles may be given.
Preporučuje se šest ciklusa liječenja VELCADEom, iako se bolesnicima za koje je odgovor prvi put zabilježen u 6. ciklusu, mogu dati dva dodatna ciklusa liječenja VELCADEom.
Six weeks after the eighth injection (fourth treatment cycle) of Xiapex
Šest tjedana nakon osme injekcije (četvrtog ciklusa liječenja) Xiapexa
Six years after vaccination, 84%, 87%, 97% and 48% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the cLIA, respectively, and 89%, 86%, 100% and 82% were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 seropositive in the IgG LIA, respectively.
Šest godina nakon cijepljenja, 84% bilo je seropozitivno na tip 6 HPV-a, 87% na tip 11; 97% na tip 16 i 48% na tip 18, na temelju nalaza cLIA testa, a na temelju nalaza IgG LIA testa 89% bilo je seropozitivno na tip 6 HPV-a, 86% na tip 11; 100% na tip 16 i 82% na tip 18.
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 % (95 % CI: -7.8 8.2).
73,0% bolesnika liječenih levetiracetamom i 72,8% bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2% (95% CI: 7,8 - 8,2).
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 % (95 % CI: -7.8 8.2).
73,0% bolesnika liječenih levetiracetamom i 72,8% bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2% (95% CI: 7,8 8,2).
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 % (95 % CI:-7.8 8.2).
73,0% bolesnika liječenih levetiracetamom i 72,8% bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2% (95% CI: 7,8 8,2).
Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI: -7.8 8.2).
73,0% bolesnika liječenih levetiracetamom i 72,8% bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2% (95% CI: -7,8 8,2).
Sixteen ferrets were divided into two cohorts and were vaccinated on days 0 and 21 with 7.5 µg of the A/Vietnam/1203/2004 vaccine or were sham vaccinated.
Šesnaest je afričkih tvorova podijeljeno u dvije kohorte te su cijepljeni 0. i 21. dana s 7,5 µg cjepiva A/Vietnam/1203/2004 ili su lažno cijepljeni.
Sixty percent of patients were male and 99.6% were Caucasian ; the median age was 52 years with 21% of patients being ≥65 years, 98.4% had ECOG status of 0 or 1, and 97% of patients had metastatic disease.
Šezdeset posto bolesnika su bili muškarci i 99,6% bijele rase; medijan dobi je bio 52 godine s 21% bolesnika ≥ 65 godina, 98,4% je imalo ECOG status 0 ili 1, a 97% bolesnika je imalo metastatsku bolest.
Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction.
U šezdeset i sedam posto (67%) bolesnika pojavila se najmanje jedna reakcija povezana s infuzijom.
Sixty seven percent of patients were Caucasian, 15% African American/African heritage and 11% Asian; 26% of patients were Hispanic/Latino.
Šezdeset i sedam posto bolesnika bili su bijelci, 15% Afroamerikanci/osobe afričkoga podrijetla, 11% Azijati, a 26% Hispanoamerikanci/Latinoamerikanci.
Sixty-eight percent (21/31) of antibody- positive patients had neutralising antibodies in vitro.
Od bolesnika pozitivnih na protutijela, 68% (21/31) je imalo neutralizirajuća protutijela in vitro.
Sixty-eight percent (21/31) of antibody-positive patients had neutralising antibodies in vitro.
Bolesnici koji su odgovorili na liječenje, % bolesnika
Sixty-five patients entered a follow-up SBS study for up to an additional 28 weeks of treatment.
Šezdeset pet bolesnika uključeno je u ispitivanje praćenja SKC-a s trajanjem do 28 dodatnih tjedana liječenja.
Sixty-five percent of patients studied in a SCN trial program with filgrastim administration, were under 18 years of age.
Šezdeset pet posto bolesnika u kliničkom programu ispitivanja primjene filgrastima kod teške kronične neutropenije bilo je mlađe od 18 godina.
Sixty-one patients completed the study (35 patients received the recommended 400/100 mg twice daily dose throughout the study).
61 bolesnik završio je studiju (35 bolesnika primalo je preporučenu dozu lijeka Kaletra 400/100 mg dva puta dnevno tijekom cijelog ispitivanja).
Sixty-one patients completed the study (35 patients received the recommended 400/100 mg twice-daily dose throughout the study).
61 bolesnik završio je studiju (35 bolesnika primalo je preporučenu dozu lijeka Kaletra 400/100 mg dva puta dnevno tijekom cijelog ispitivanja).
Sixty-six percent of placebo patients received post-study therapy compared to 30 % of pazopanib patients.
Šezdeset šest posto bolesnika iz placebo skupine je primalo terapiju nakon ispitivanja u usporedbi s 30% bolesnika iz pazopanib skupine.
Sixty-three of the 100 patients entering part II, whether assigned to placebo or canakinumab, did not experience a flare over the observation period (up to a maximum of 80 weeks).
Šezdeset tri od 100 bolesnika koji su se uključili u drugi dio, bez obzira na to je li im bio dodijeljen placebo ili kanakinumab, nije osjetilo naglo pogoršanje bolesti tijekom razdoblja promatranja (do najviše 80 tjedana).
Size 2 hard capsule (6.4x18.0 mm) with an opaque blue cap and opaque white body with “A1001” printed in black containing white to pale brown powder.
Tvrda kapsula veličine 2 (6,4 x 18,0 mm) s neprozirnom plavom kapicom i neprozirnim bijelim tijelom s oznakom „A1001” ispisanom crnom bojom koja sadrži prašak bijele do svijetlosmeđe boje.
Size “00” hard capsules with caramel body and cap.
Tvrde kapsule veličine “00” tijela i kapice žuto-smećkaste boje.
Size “3” hard capsules with orange body and cap.
Tvrde kapsule veličine “3” narančastog tijela i kapice.
sJIA Patients < 30 kg
Bolesnici sa sJIA < 30 kg
SJS and TEN have been reported.
Prijavljen je Stevens-Johnsonov sindrom i toksična epidermalna nekroliza.
SJS and TEN have been reported.
Prijavljeni su Stevens-Johnsonov sindrom i toksična epidermalna nekroliza.
SK-831 06 Bratislava
I-20010 Arluno (MI)
Skeletal Effects
Učinci na skelet
Skeletal immaturity
nezrelim kosturom
Skeletal injury
ozljeda kostiju
Skeletal morbidity rate
Stopa koštanog pobola
Skeletal morbidity rate
topa koštanog pobola
Skeletal muscle
Skeletni mišići
Skeletal-related events
Koštani događaji
Skin & subcutaneous tissue disorders
Poremećaji kože i potkožnog tkiva
Skin adhesion was measured on 2 consecutive days of 24 hours patch application.
Prianjanje flastera na kožu mjereno je dva uzastopna dana s cjelodnevnom primjenom svakog flastera u trajanju od 24 sata.
SKIN AND
POREMEĆAJI KOŽE
Skin and
Poremećaji
Skin and
Poremećaji kože
Skin and
Poremećaji kože i
Skin and
prsnog koša i
Skin and
žuči
Skin and allergic reactions
Kožne i alergijske reakcije
Skin and allergic reactions at the injection site
Kožne i alergijske reakcije na mjestu injiciranja
Skin and allergic reactions at the injection site: The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation.
Znakovi mogu uključivati crvenilo, neuobičajeno jaku bol prilikom injiciranja, svrbež, osip, oticanje ili upalu.
Skin and eye contact, oral ingestion
Kontakt s kožom i očima, ingestija
Skin and fat Liver
Koža i masno tkivo Jetra
Skin and hair changes
Promjene na koži i kosi
Skin and hair: cold sores, tingling or numbness of the skin; reduced feeling or sense of touch; skin rash, patchy skin rash, red skin; red raised skin rash sometimes with pus-filled blisters; hot, tender and red skin, sometimes with fever and chills; increased sweating; skin disease with thick patches of red skin – often with silvery scales
Koža i kosa: bolni mjehurići obično nakon povišene temperature, trnci ili utrnulost kože; oslabljeni osjećaj ili osjet dodira; osip kože, mrljasti osip kože, crvenilo kože; crveni uzdignuti osip kože, ponekad s gnojnim mjehurićima; vruća, osjetljiva i crvena koža, ponekad uz vrućicu i zimicu; pojačano znojenje; kožna bolest sa zadebljalim crvenim mrljama na koži – često sa srebrnkastim ljuskama
Skin and hair: dry skin, itching, rash; hair loss or thinning of hair
Koža i kosa: suha koža, svrbež, osip; ispadanje ili stanjivanje kose
Skin and hair: hives; open sore; intolerance to heat; markedly red face; pale face; yellow skin; rash due to sunlight; wound not healing normally
Koža i kosa: koprivnjača; otvorene rane; nepodnošenje vrućine; zamjetno crvenilo lica; bljedilo lica; žutilo kože; osip izazvan sunčevim svjetlom; rane koje otežano zacjeljuju
Skin and hair: reddening of the skin; bacterial skin infection
Koža i kosa: crvenilo kože; bakterijska infekcija kože
Skin and hair: Severe rash, which may be accompanied by fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidney or lung (a reaction called DRESS); serious skin reaction, including blistering or peeling of the skin (a reaction called Stevens-Johnson syndrome)
Koža i kosa: težak osip, uz koji se mogu javiti vrućica, umor, oticanje lica ili limfnih žlijezda, povećan broj eozinofila (jedne vrste bijelih krvnih stanica), učinci na jetru, bubrege ili pluća (reakcija koja se naziva DRESS); ozbiljna kožna reakcija, uključujući nastanak mjehurića ili ljuštenje kože (reakcija koja se naziva Stevens-Johnsonovim sindromom)
Skin and nail problems - signs may include itching, dry skin, rash, redness around the fingernails.
Problemi s kožom i noktima – znakovi mogu uključivati svrbež, suhu kožu, osip, crvenilo oko noktiju.
Skin and soft tissue infections in dogs:
Infekcije kože i mekog tkiva u pasa:
Skin and sub- cutaneous tissue disorders
Poremećaji kože i potkožnog tkiva
Skin and sub-cutaneous tissue disorders
Poremećaji kože i potkožnog tkiva
Skin and subcutan eous
Poreme ćaji kože i potkožn og tkiva
Skin and subcutaneo us tissue disorders
Poremećaji kože i potkožnog tkiva
SKIN AND SUBCUTANEOUS
POREMEĆAJI KOŽE I
Skin and subcutaneous
Poremećaji kože i potkožnog tkiva
Skin and subcutaneous disorders:
Poremećaji kože i potkožnog tkiva:
Skin and subcutaneous tissue
Poremećaji kože i potkožnog
Skin and subcutaneous tissue
Poremećaji kože i potkožnog tkiva
Skin and subcutaneous tissue
Poremećaji kože, potkožnog i mekog tkiva
Skin and Subcutaneous Tissue Disorders
i potkožnog tkiva
Skin and subcutaneous tissue disorders
Klasifikacija organskih sustava
Skin and subcutaneous tissue disorders
konvulzije, parosmija, hipokinezija, disgrafija
Skin and subcutaneous tissue disorders
kože i potkožnog tkiva
Skin and subcutaneous tissue disorders
Krvožilni poremećaji
Skin and subcutaneous tissue disorders
Opći poremećaji i
Skin and subcutaneous tissue disorders
Opći poremećaji i reakcije na mjestu primjene
Skin and subcutaneous tissue disorders
Poreme ćaji kože i potkožn og tkiva
Skin and subcutaneous tissue disorders
Poremeć aji kože i potkožn og tkiva
Skin and subcutaneous tissue disorders
Poremeć aji kože i potkožno g tkiva
Skin and subcutaneous tissue disorders
Poremećai kože i potkožnog tkiva
Skin and subcutaneous tissue disorders
Poremećaj i kože i potkožnog tkiva
Skin and subcutaneous tissue disorders
Poremećaji koţe i potkoţnog tkiva
Skin and subcutaneous tissue disorders
Poremećaji kože
Skin and subcutaneous tissue disorders
Poremećaji kože i
Skin and subcutaneous tissue disorders
Poremećaji kože i potkožnog
Skin and subcutaneous tissue disorders
Poremećaji kože i potkožnog sustava
Skin and subcutaneous tissue disorders
Poremećaji kože i potkožnog tkiva:
Skin and subcutaneous tissue disorders
Poremećaji kože i potkožnogtkiva
Skin and subcutaneous tissue disorders
Poremećaji kože i supkutanog tkiva
Skin and subcutaneous tissue disorders
Poremećaji metabolizma i prehrane
Skin and subcutaneous tissue disorders
Poremećaji mišićno
Skin and subcutaneous tissue disorders
Poremećaji probavnog sustava
Skin and subcutaneous tissue disorders
Poremećaji živčanog sustava
Skin and subcutaneous tissue disorders
vezivnog tkiva
Skin and subcutaneous tissue disorders Common: sweating
Poremećaji kože i potkožnog tkiva Često: znojenje
Skin and subcutaneous tissue disorders Erythema multiforme, lichen planus
Poremećaji kože i potkožnog tkiva Erythema multiforme, lichen planus
Skin and subcutaneous tissue disorders Uncommon: rash, pruritus, hyperhidrosis Rare: urticaria, erythema
Poremećaji kože i potkožnog tkiva Manje često: osip, pruritus, hiperhidroza Rijetko: urtikarija, eritem
Skin and subcutaneous tissue disorders urticaria, pruritus, rash
Poremećaji kože i potkožnog tkiva urtikarija, pruritus, osip
Skin and subcutaneous tissue disorders Very common: alopecia
Poremećaji kože i potkožnog tkiva Vrlo često: alopecija
Skin and subcutaneous tissue disorders Very rare Sweating, rash
Poremećaji kože i potkožnog tkiva Vrlo rijetko znojenje, osip
Skin and subcutaneous tissue disorders*
Poremećaji kože i potkožnog tkiva
Skin and subcutaneous tissue disorders/Injury, poisoning and procedural complications
Poremećaji kože i potkožnog tkiva/Ozljede, trovanja i proceduralne komplikacije
Skin and subcutaneous tissue disorders:
Poremećaji kože i potkožnog tkiva
Skin and subcutaneous tissue disorders:
Poremećaji kožne i potkožnog tkiva
Skin and subcutaneous tissue disorders:
Poremećaji živčanog sustava:
Skin and subcutaneous tissue disorders: Rare: urticaria.
Poremećaji kože i potkožnog tkiva: Rijetko: urtikarija.
Skin and subcutaneous tissue disorders: Uncommon: Rash/urticaria.
Poremećaji kože i potkožnog tkiva: Manje često: osip/urtikarija
Skin and subcutaneous tissue disorders: Urticaria, angioedema, pruritus
Poremećaji kože i potkožnog tkiva: urtikarija, angioedem, svrbež
Skin and subcutaneous tissues disorders
Poremećaji kože i
Skin and subcutaneous tissues disorders
Poremećaji kože i potkožnog tkiva
Skin and subcutanesous tissue disorders hyperhydrosis
Poremećaji kože i potkožnog tkiva hiperhidroza
Skin and tissue disorders
Poremećaji kože i mekih tkiva
Skin around the vein is red and painful (superficial vein thrombophlebitis)
koža oko vene je crvena i bolna (tromboflebitis površinskih vena)
Skin around the vein is red and painful (superficial vein thrombophlebitis).
koža oko vene je crvena i bolna (tromboflebitis površinskih vena).
Skin blistering (including blisters that burst)
Mjehurići po koži (uključujući mjehure koji pucaju).
Skin blistering (including blisters that burst).
Mjehurići po koži (uključujući mjehure koji pucaju).
Skin blisters
mjehuri na koži
Skin burning, herpes simplex, alcohol intolerance (facial flushing or skin sensitivity after alcohol intake), skin tingling, hyperaesthesia, acne and fungal dermatitis occurred more often in the tacrolimus treatment group.
Žarenje kože, herpes simpleks, nepodnošenje alkohola (crvenilo lica uz osjećaj vrućine i osjetljivost kože nakon uzimanja alkohola), trnci u koži, hiperestezija, akne i gljivični dermatitis javljali su se češće u skupini liječenoj takrolimusom.
Skin cancer
rak kože
Skin cancer or non cancerous growth of the skin and fungal infections of the skin and vagina
rak kože ili izrasline na koži koje nisu povezane sa rakom i gljivične infekcije kože i rodnice
Skin cancer*
karcinom kože
Skin cancer, benign neoplasm of skin
karcinom kože, dobroćudna neoplazma kože
Skin cancer, benign neoplasm of skin
rak kože, dobroćudna novotvorina kože
Skin changes (e.g. red skin);
Promjene kože (npr. crvena koža) ;
Skin changes (e.g. red skin);
Promjene kože (npr. crvena koža);
Skin changes at the injection site
Kožne promjene na mjestu injiciranja
Skin changes at the injection site (lipodystrophy)
Kožne promjene na mjestu injiciranja (lipodistrofija)
Skin changes where the injection is given: If you inject insulin too often at the same place, the skin may either shrink (lipoatrophy) or thicken (lipohypertrophy).
Ako injicirate inzulin prečesto na istome mjestu, koža se na tom mjestu može stanjiti (lipoatrofija) ili zadebljati (lipohipertrofija).
Skin changes where you give the injection (‘lipodystrophy’) – the fatty tissue under the skin may shrink (‘lipoatrophy’) or get thicker (‘lipohypertrophy’).
vrbež promjene na koži na mjestu injiciranja (‘lipodistrofija’) – potkožno masno tkivo može se smanjiti (‘lipoatrofija’) ili povećati (‘lipohipertrofija’).
Skin changes where you use the injection (lipodystrophy): It is not known if Ryzodeg may cause lipodystrophy but such skin changes have been seen with other types of insulin.
Promjene na koži na mjestu gdje primjenjujete injekciju (lipodistrofija): Nije poznato da li Ryzodeg može uzrokovati lipodistrofiju, ali takve promjene na koži javile su se s drugim vrstama inzulina.
Skin chapped
isušena koža
Skin colour change in patches (vitiligo), dry skin, redness of the skin, unusual hair loss or thinning
mrljaste promjene boje kože (vitiligo), suha koža, crvenilo kože, neuobičajen gubitak ili stanjivanje kose